When should ranolazine be considered for the treatment of chronic angina?
Bernard R Chaitman
Correspondence St Louis University School of Medicine, 1034 South Brentwood, Boulevard, Suite 1550, St Louis, MO 63117, USA
Email chaitman@slu.edu
This article has no abstract so we have provided the first paragraph of the full text.
In January 2006, extended-release ranolazine was approved in the US for use as an add-on therapy in patients with chronic angina. Two randomized, placebo-controlled trials of patients with chronic angina showed that ranolazine significantly increased total exercise duration, time to angina onset, and ischemic ST-segment depression without a clinically important change in rest or exercise heart rate and blood pressure. The CARISA and ERICA trials also found that the drug significantly decreased angina attack frequency and sublingual nitroglycerin consumption.1
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
